Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Tislelizumab Combined Treatment in Refractory Natural Killer/T-cell Lymphoma

NCT05058755 is registered in ClinicalTrials.gov with Xinhua Hospital, Shanghai Jiao Tong University School of Medicine as lead sponsor.

NCT NCT05058755
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05058755 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Tislelizumab Combined Treatment in Refractory Natural Killer/T-cell Lymphoma
Lead sponsor
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Phase
Not applicable
Overall status
Completed
Start date
September 17, 2021
Completion date
December 30, 2023
Enrollment
62 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

natural killer/t-cell lymphoma, nasal and nasal-type